systemic necrotizing vasculitis
Jump to navigation
Jump to search
Management
- lower dose cyclophosphamide in initial treatment of older patients associated with fewer serious adverse effects without difference in relapse rates
- maintenance therapy
- azathioprine
- rituxumab may be better than azathioprine for ANCA-associated vasculitis
- rituxumab used for induction in patients with ANCA-associated vasculitis
- prognaosis: relapse common
More specific terms
- allergic angiitis & granulomatosis of Churg-Strauss; eosinophilic granulomatosis with polyangiitis (EGPA)
- classic polyarteritis nodosa (PAN)
- granulomatosis with polyangiitis; Wegener's granulomatosis
- microscopic polyangiitis
Additional terms
References
- ↑ Coblyn JS Lower-Dose Therapy Is Associated with Fewer Serious Adverse Events in Elders with Systemic Necrotizing Vasculitis. NEJM Journal Watch. May 5, 2015 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
Pagnoux C, Quemeneur T, Ninet J et al Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: Results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis & rheumatology 2015 Apr; 67:1117. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25693055